Shannon Goldsmith, DO
Family Medicine · Ellisville, MSNPI 1477748648
Payments from drug & device makers
Across 348 payments — averaging $13.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$973
- Novo Nordisk$476
- GSK$464
- Johnson & Johnson$355
- Takeda Pharmaceuticals U.S.A., Inc.$269
- Astellas Pharma US Inc$246
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,55098%
- Education$952%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 100 | $973 |
| Novo Nordisk | 33 | $476 |
| GSK | 50 | $464 |
| Johnson & Johnson | 24 | $355 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $269 |
| Astellas Pharma US Inc | 11 | $246 |
| Lilly USA, LLC | 14 | $227 |
| Amgen | 13 | $207 |
| Merck | 10 | $171 |
| Pfizer | 9 | $169 |
| Boehringer Ingelheim | 8 | $112 |
| Bayer | 6 | $90 |
| Amarin Pharma, Inc. | 6 | $84 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $79 |
| AstraZeneca | 5 | $70 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $70 |
| Exact Sciences | 3 | $59 |
| Ironshore Pharmaceuticals Inc. | 3 | $54 |
| Daiichi Sankyo Inc. | 3 | $50 |
| Shield Therapeutics Inc | 3 | $44 |
| Abbott | 2 | $42 |
| Novartis | 2 | $37 |
| Medtronic | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| IBSA Pharma Inc. | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| Sanofi Pasteur Inc. | 1 | $26 |
| Genentech USA, Inc. | 2 | $26 |
| Shire North American Group Inc | 2 | $24 |
| Stryker | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Biogen | 1 | $12 |
How this compares
$4,645 in reported general payments places this provider in the 80th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 125 | $146,597 |
| MounjaroTirzepatide | 70 | $95,748 |
| JardianceEmpagliflozin | 90 | $80,275 |
| RybelsusSemaglutide | 32 | $39,863 |
| JanuviaSitagliptin Phosphate | 44 | $38,650 |
| LinzessLinaclotide | 32 | $37,681 |
| TrulicityDulaglutide | 29 | $34,510 |
| EliquisApixaban | 34 | $31,311 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $30,352 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $22,448 |
| VraylarCariprazine Hcl | 13 | $18,002 |
| MyrbetriqMirabegron | 17 | $15,461 |
| XareltoRivaroxaban | 13 | $11,375 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $11,266 |
| TradjentaLinagliptin | 14 | $10,323 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $476 | $186,460157 claims |
| Lilly USA, LLCMounjaro, Trulicity | $227 | $130,25899 claims |
| Boehringer IngelheimJardiance, Tradjenta | $112 | $90,598104 claims |
| AbbVieLinzess, Vraylar, Synthroid | $973 | $61,107135 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta | $464 | $45,06888 claims |
| MerckJanuvia, Janumet | $171 | $44,68856 claims |
| PfizerEliquis, Prempro | $169 | $33,66345 claims |
| Astellas Pharma US IncMyrbetriq | $246 | $15,46117 claims |
| Johnson & JohnsonXarelto | $355 | $11,37513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Ellisville
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
- Kristi TrimmRidgeland$1.2M
- Keith StokesLexington$660K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.